Interventions with Potential to Mitigate Injection Site Reactions Following Subcutaneous Elamipretide Administration: A Phase 1, Crossover Study
Shortened Title: Mitigating Elamipretide ISRs
Authors: Sandrin C. Bergheanu1, Benjamin McNeil2, Alana Sullivan1, Laura E. Kropp1, Li Zhang 2, Lisa A. Beck3, Anthony Abbruscato 1
Affiliations: 1Stealth BioTherapeutics Inc., Needham, MA, USA; 2Division of Allergy and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA;3Carol & Lowell Goldsmith Professor of Dermatology, Medicine & Pathology, University of Rochester Medical Center, Rochester, NY, USA
Corresponding author: Abbruscato A
ORCID iD : 0000-0001-9050-9385
Principal Investigator : The authors confirm that the Principal Investigator for this paper is Robert Bass, MD and that he had direct clinical responsibility for patients. He is not listed as an author as he did not contribute to the writing of this manuscript.
Keywords: Elamipretide, Injection Site Reaction, mitigation, mometasone, safety, tolerability, MRGPRX2
Word count : <<4451/4000>>
Table count : 5
Figure count : 4